Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cannabis compounds may rewire memory retrieval, brain scans suggest

NCT ID NCT07679581

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 01, 2026 · Last updated Jul 02, 2026 · Updated 1 time

Summary

This study investigates how THC and CBD in cannabis affect recognition memory in healthy adults who use cannabis regularly. Participants perform a memory task after smoking cannabis and on a separate sober day, while their brain activity is recorded via EEG. Blood samples measure THC and CBD levels. The goal is to understand how different cannabis strains influence memory processes like familiarity and recollection.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Cannabis (smoked flower)
What this could lead to
If successful, this could clarify how different cannabis compounds affect memory, guiding safer use or therapeutic applications.
What could go wrong
This is a small, early-stage observational study in healthy regular users, so results may not apply to occasional users or people with memory disorders.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 64 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2025

Expected to finish

May 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Community sample of healthy, regular cannabis users in the Boulder/Denver areas.

Ages

21 to 40 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

1. Must be between the ages of 21 and 40 and provide informed consent; 2. Must be right-handed (Laterality Quotient \> 60 on Edinburgh Handedness Inventory - Short Form136); 3. Heavy users (HU) in Experiments 1, 2, 3, and 4: 1. Must use cannabis at least 4 days during the month; 2. Must be a cannabis user for at least a year; 4. Non-users (NU) in Experiment 2: 1. Must not have used cannabis for prior 6 months; 2. Must have at least one episode of lifetime cannabis use; 5. Must self-report not using other illicit recreational drugs (e.g., cocaine, benzodiazepines (non-prescription), opiates (non-prescription), MDMA, sedatives, or methamphetamine) in the past 30 days, during the Pre-Screening; 6. Must not test positive on a urine toxicology test for drugs of abuse at the Baseline Appointment (TDS); 7. Must not be using psychotropic medications, however anti-depressant, non-benzodiazepine anti-anxiety, and ADHD medications are ok. ADHD medication users must be willing to abstain from ADHD medication use on appointment days; ADHD medications, even extended-release forms, are short acting and medication" holidays" (e.g., on weekends and holidays) are routine in individuals prescribed ADHD medications, without adverse effects. 8. Must not be a regular nicotine user (≤4 days per week; cigarette, E-cigs, or smokeless); 9. Must not have used caffeine or nicotine (cigarette, E-cigs, or smokeless) for 4 hours; 10. Must have a breath alcohol level of 0 at screening (to sign consent form); 11. Must not be actively seeking or in treatment for any substance use disorder (drug use levels will be carefully monitored via Timeline Follow Back (TLFB) throughout the study to assess any confounding influences of drug or alcohol use; 12. Female subjects must not be or trying to become pregnant (as indicated by a pregnancy test \& screening form administered at Baseline); 13. Must not be in treatment for psychotic disorder or bipolar disorder; or have a history with these disorders; 14. Must not have any physical characteristics (e.g., thick hair, head size exceeding the limit of the net, dyed hair) or experience any technical difficulties during testing that result in a poor-quality EEG recording. 15. Participants in Experiment 4 a. Must not have participated in Experiment 3

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cannabis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Center for Innovation and Creativity (CINC)

    RECRUITING

    Boulder, Colorado, 80301, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.